Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become established as blood glucose-lowering therapies that should be considered in people with type 2 diabetes if glycemic targets are not met with lifestyle measures and metformin [1], especially in those with, or at high risk of, cardiovascular (CV) disease [2]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.